PerkinElmer Invests in Carterra, the Leader in Label-Free High Throughput Antibody Screening and Characterization
Retrieved on:
Monday, December 14, 2020
Traditional antibody discovery relies on low-resolution screening techniques to triage antibody libraries down to a small number of candidates, which are then characterized on low-throughput biosensors.
Key Points:
- Traditional antibody discovery relies on low-resolution screening techniques to triage antibody libraries down to a small number of candidates, which are then characterized on low-throughput biosensors.
- The Carterra LSA platform turns that model on its head by allowing the rapid and high-resolution characterization of entire antibody libraries for binding kinetics and epitope, thereby combining screening and characterization into one step.
- Carterra is the leading provider of high throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates.
- The LSA combines patented microfluidics technology with real-time high throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening.